Lipid profile changes by high activity anti-retroviral therapy

详细信息    查看全文

• 作者：M. Duro^a ; ^b ; ^f ; R. Sarmento-Castro^c ; ^d ; C. Almeida^b ; ^{calmeida@ufp.edu.pt} ; R. Medeiros^b ; ^e ; I. Rebelo^a
• 关键词：Lipid profile ; Dyslipidaemia ; Lipodystrophy ; HIV ; HAART ; PI ; NRTI ; NNRTI
• 刊名：Clinical Biochemistry
• 出版年：2013
• 出版时间：June, 2013
• 年：2013
• 卷：46
• 期：9
• 页码：740-744
• 全文大小：211 K

文摘

Objective

Study of the lipid profile in patients infected with HIV treated with different combinations of high activity anti-retroviral therapy (HAART).

Design and methods

A retrospective cohort study of the lipid profile in patients undergoing HAART. The study analyzes the evolution of concentrations of triglycerides (TG), total cholesterol (TC), LDL-cholesterol (LDLc) and HDL-cholesterol (HDLc) in a period of at least 3 years of treatment. From a total of 750 clinical cases analyzed in Hospital Joaquim Urbano (Oporto, Portugal) 124 patients were selected for this study.

Results

After 3 years of treatment, we observed the development of dyslipidaemia by increases in TG (17 % ), TC (29 % ) and LDLc (9 % ), particularly in patients treated with a combination of drugs which included protease inhibitors (PI). Moreover, the non-nucleoside reverse transcriptase inhibitors (NNRTI) were associated with better lipid profile. The increase of 46 % in HDLc was the most surprising finding.

Conclusions

The results indicate that patients with HAART have a more atherogenic lipidic profile with increased TC, LDLc and TG levels. Since the effectiveness of NNRTI is similar to that of PI, but with a smaller atherogenic profile, it should be the first choice drug to be selected in the HIV treatment.